Gilead Sciences, Inc. bought $15.0M of Arcus Biosciences (RCUS)
Executed Feb 18 2025, disclosed Feb 20 2025, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Feb 20 2025), the stock returned -17.3% (delay-adjusted); from the execution session (Feb 18 2025), -29.8%. Derived: entry at the session's open, exit at the close 20 sessions later.
Gilead Sciences, Inc. (10% owner) filed 4 Form 4 reports as a reporting entity in the past 24 months (4 purchases, 0 sales, 1 filed past the two-business-day deadline), most often in Assembly Biosciences, Inc. (ASMB). Across 4 priced purchase filings, the average 21-session return was +4.2% from execution and +0.5% from disclosure (delay-adjusted; derived). The largest single filing was $55.0M of ASMB (as filed), executed Aug 8 2025.
Healthcare · Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→